Keith Katkin - 10 Jan 2026 Form 4 Insider Report for Eledon Pharmaceuticals, Inc. (ELDN)

Reporting relationship: Director
Issuer ticker: ELDN
Reported as of: 10 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 16 Jan 2026, 17:00:06 UTC
Prior SEC filing: 28 May 2025
Next SEC filing: 06 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Paul Little, as attorney-in-fact for Keith Katkin

Key filing fact

Keith Katkin filed Form 4 for Eledon Pharmaceuticals, Inc. (ELDN) on 16 Jan 2026.

Key facts

This page summarizes Keith Katkin's Form 4 filing for Eledon Pharmaceuticals, Inc. (ELDN).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 16 Jan 2026, 17:00.

Change

Previous filing in this sequence was filed on 28 May 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001314596 Primary reporting owner

Katkin Keith

Relationship: Director
Address: C/O ELEDON PHARMACEUTICALS, INC., 19800 MACARTHUR BLVD STE. 250, IRVINE
Signature: /s/ Paul Little, as attorney-in-fact for Keith Katkin
Signature date: 16 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ELDN transaction

Common Stock

Options Exercise

Transaction value: $0
Shares: +8,575
Change %
Price: $0.000000
Shares after: 8,575
Date: 10 Jan 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ELDN transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value: $0
Shares: -8,575
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 10 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 8,575
Exercise price
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents shares issuable on settlement of restricted stock units ("RSUs") for common stock on a one-for-one basis granted to the reporting person. The RSUs were issued on January 10, 2025 and vested 100% on January 10, 2026.